AnGes

AnGes Liabilities

The The Liabilities of AnGes (4563.T) as of Oct 19, 2026 is 2.33 B JPY. In the previous year, The Liabilities was 2.51 B JPY — a change of -7.25% (lower).

Liabilities

2.33 BJPY

YoY

-7.25%

Last updated:

In 2025, AnGes's total liabilities amounted to 2.33 B JPY, a -7.25% difference from the 2.51 B JPY total liabilities in the previous year.

The AnGes Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
316.21 M JPY
Jan 1, 2019
469.25 M JPY
Jan 1, 2020
5.67 B JPY
Jan 1, 2021
6.82 B JPY
Jan 1, 2022
8.40 B JPY
Jan 1, 2023
2.79 B JPY
Jan 1, 2024
2.51 B JPY
Jan 1, 2025
2.33 B JPY
The AnGes Liabilities history
YEARLiabilitiesYoY
2.33 BJPY-7.25%
2.51 BJPY-9.94%
2.79 BJPY-66.77%
8.40 BJPY+23.08%
6.82 BJPY+20.20%
5.67 BJPY+1,109.37%
469.25 MJPY+48.40%
316.21 MJPY-7.47%
341.73 MJPY-48.98%
669.82 MJPY+26.23%
530.64 MJPY+14.19%
464.70 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AnGes Stock analysis

What does AnGes do? AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing AnGes's Liabilities

AnGes's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating AnGes's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing AnGes's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

AnGes's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in AnGes’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about AnGes stock

The Liabilities of AnGes is 2.33 B JPY in 2025.

The Liabilities of AnGes changed from 2.51 B JPY to 2.33 B JPY, representing a -7.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities AnGes since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's AnGes historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AnGes

All Key Metrics — AnGes